- Home
- ADCT
ADCT
ADC Therapeutics SA
as 11-01-2025 4:27am EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Upcoming Earnings Alert:
Get ready for potential market movements as ADC Therapeutics SA ADCT prepares to release earnings report on 07 Nov 2025.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 380.2M | IPO Year: | 2020 |
| Target Price: | $7.60 | AVG Volume (30 days): | 984.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $4.80 | Next Earning Date: | 11-07-2025 |
| Revenue: | $77,246,000 | Revenue Growth: | 15.73% |
| Revenue Growth (this year): | 11.78% | Revenue Growth (next year): | 4.83% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement
Zacks
19 days ago
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
MT Newswires
20 days ago
ADC Therapeutics Plans $60 Million Private Placement
PR Newswire
20 days ago
ADC Therapeutics Announces $60 Million Private Placement
Simply Wall St.
2 months ago
Owning 30% shares,hedge funds owners seem interested in ADC Therapeutics SA (NYSE:ADCT),
PR Newswire
5 months ago
ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
MT Newswires
5 months ago
ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site
PR Newswire
5 months ago
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.